Overview

A Study of Sublingually Administered (S)-Ketamine Oral Solution in Healthy Participants

Status:
Completed
Trial end date:
2020-08-17
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the plasma pharmacokinetic (PK) profile following the single ascending dose (SAD) levels of an (S)-ketamine oral solution for sublingual administration in healthy participants.
Phase:
Phase 1
Details
Lead Sponsor:
Janssen Research & Development, LLC
Treatments:
Esketamine
Ketamine
Pharmaceutical Solutions